Cargando…
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
PURPOSE: The risk of immune checkpoint inhibitor therapy–related GI adverse events in patients with cancer and inflammatory bowel disease (IBD) has not been well described. We characterized GI adverse events in patients with underlying IBD who received immune checkpoint inhibitors. PATIENTS AND METH...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7030892/ https://www.ncbi.nlm.nih.gov/pubmed/31800340 http://dx.doi.org/10.1200/JCO.19.01674 |